Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer.

Oncol Rep · 2015 · PMC4583528 · PMID 26324075

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp<0.0001actually significant

Kaplan-Meier analysis showed highly significant retardation of progression for trametinib or the combination (p<0.0001 vs. vehicle), but not for single agent pazopanib ( Fig. 2C ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.